DS
AVXL icon

David Shaw’s Anavex Life Sciences AVXL Stock Holding History

David Shaw’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,000
Closed -$160K – 4536
2025
Q4 		$160K Buy
+45,000
New +$276K ﹤0.01% 4358

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

David Shaw's AVXL Position: Q2 2026 in Review

David Shaw increased its Anavex Life Sciences (AVXL) stake by 157% in Q2 2026, buying an estimated $209K and bringing the position to 115,462 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #4414.

David Shaw first reported a position in AVXL in Q2 2016 and has held it in 23 quarters since. The position peaked at $3.81M in Q1 2022. 177 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • David Shaw held 115,462 shares of Anavex Life Sciences worth $299K as of Q2 2026.
  • David Shaw bought 70,606 Anavex Life Sciences shares in Q2 2026, an estimated $209K.
  • Anavex Life Sciences made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4414 holding.
  • David Shaw first reported a position in Anavex Life Sciences in Q2 2016 and has held it in 23 quarters since.
  • David Shaw's Anavex Life Sciences position peaked at $3.81M in Q1 2022.
  • 177 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.